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Multiplemyelomaisanincurableplasmacellmalignancythatisoftenaccompaniedbyrenalfailure;thereareanumber ofpotential
causes of this, of which cast nephropathy is the most important. Renal failure is highly signiﬁcant in myeloma, as patient survival
can be stratiﬁed by the severity of the renal impairment. Consequently, there is an ongoing focus on the pathological basis of cast
nephropathy and the optimal treatment regimens in this setting, including eﬀective chemotherapy regimens to reduce light chain
production and emerging extracorporeal techniques to remove circulating light chains. This paper bridges recent advances in the
pathogenesis and management of cast nephropathy in multiple myeloma.
1.Introduction
The kidneys are a common target for injury in a large
number of acute and chronic diseases that initially develop
at nonrenal sites. Where renal injury develops as a secondary
consequence of nonrenal disease, then (i) the factors that
cause this injury are often complex; (ii) the involvement of
the kidneys and the developmentof subsequentacute kidney
injury (AKI) or chronic kidney disease (CKD) has a delete-
rious eﬀect on subsequent clinical outcomes. The eﬀective
management of kidney disease is an important factor in
improving the long-term outcomes of the aﬀected individ-
ual. Multiple myeloma (MM) is commonly complicated by
kidney injury with a major impact on long-term outcomes;
therefore understanding the nature of the kidney damage
and the treatment options that are available are crucial for
improving outcomesfor people with MM and kidney injury.
In this paper we will overview the current status of basic and
clinical science in this area and show how increasing knowl-
edgeinboththeseareasisleadingtoimprovementsinclinical
outcomes.
2.MultipleMyeloma and theKidneys
Multiple myeloma (MM) is a haematological malignancy
characterised by clonal proliferation of plasma cells and
associated with end-organ damage. There is production of
a monoclonal immunoglobulin (Ig) in over 80% of those
aﬀected; each intact monoclonal Ig will include either a
kappa light chain (LC) isotype or a lambda LC isotype; in
the large majority of cases of intact monoclonal Ig in MM
there is excess production of the relevant monoclonal LC,
and in around 20% of cases there is LC monoclonality with
no detectable intact immunoglobulin [1]. This detectable Ig
LC is often referred to as free light chain (FLC).
The incidence of new-onset (ﬁrst diagnosis) MM in the
United Kingdom is around 6.5 per 100,000 in Caucasians,
10-9-18.2/100,000 in Blacks, and 3.6–6.4/100,000 in Asians
[2]. At presentation at least 50% of patients will have AKI
of a variable degree, and around 10% have severe AKI from
which they will die within weeks unless they are treated with
renal replacement therapy by dialysis [3]. The prognosis for
patients with MM and AKI is worse than that for those with2 Bone Marrow Research
Figure 1: Renal biopsy showing cast nephropathy: distal tubular
casts and interstitial inﬂammationand ﬁbrosis.
normal renal function [4]. This directly relates to the severity
of AKI at time of presentation, such that those who require
and receive dialysis treatment have a median survival of less
than 12 months [5].
There are a number of factors that can contribute to
the development of AKI in MM; these include dehydration,
hypercalcaemia, and the ingestion of nephrotoxic drugs [6].
It is important to note that cast nephropathy may not
be the sole pathology in patients with MM and AKI; for
example, there may be concomitant amyloid or another
renal pathology unrelated to MM. All these factors have the
potential to trigger the development of cast nephropathy,
w h i c hi st h ec o m m o n e s tc a u s eo fs e v e r eA K I .S e v e r eA K Ii n
MM is a major medical emergency, as it is associated with a
high risk of early death. Historically, less that 20% of people
with MM require dialysis at or shortly after presentation
recover independent kidney function [5]. As a consequence,
there is a major focus on understanding the biological basis
for the development of AKI in MM. In addition, the eﬃcacy
of novel chemotherapies for promoting better outcomes is
under evaluation. Finally, with the introduction of protein-
permeable dialysers into clinical practice, there is continuing
interest in the clinical utility of extracorporeal removal of
light chains to improve renal recovery.
3.The PathogenicBasisof CastNephropathyin
MultipleMyeloma
Cast nephropathy is characterised by the presence of frac-
tured, waxy casts formed of FLC and uromodulin (Figure 1)
[7, 8]. These casts precipitate out in the distal tubules
resulting in tubular obstruction; there is also associated
tubulointerstitialinﬂammation, which may inpart berelated
to a direct proinﬂammatory eﬀect of FLC on proximal
tubular epithelial cells (PTEC) [7, 8].
To fully understand the pathogenesis of cast formation
it is necessary to understand the renal handling of FLC
(Figure 2). Serum FLCs are relatively freely ﬁltered at the
glomerulus because of their size (22.5kD for Kappa (κ)a n d
45kDfor Lambda (λ)) and cationic net charge; the glomeru-
lar sieving coeﬃcient for free Kappa LC has been calculated
at 0.09 [9]. As there are detectable levels of polyclonal FLC
in the serum of normal individuals (κ at 3.3 to 19.4mg/L;
λ at 5.7 to 26.3mg/L), it can be extrapolated that in health
between 100–600mg/24hr of FLC are presented at the renal
tubule; as there are minimal levels of FLC present in the
urine this indicates a high capacity for reabsorption of FLC
by the tubules [10]. This process of FLC reabsorption takes
place at PTEC through receptor-mediated interactions, and
free LCs in tubular ultraﬁltrate are taken up by the tandem
receptors cubilin/megalin, with subsequent endocytosis via
the endosomal/lysosomal pathway; some FLC clones bind
preferentially to megalin and some to cubilin [11–13]. After
endocytosis the FLCs undergo vesicular traﬃcking, which is
dependent upon acidiﬁcation of the vesicle. However not all
FLC digestion is conﬁned to lysosome, and there may be
some degradation of FLC bound to the PTEC membrane
[12].
There is no evidence to date that endocytosis of poly-
clonal FLC activates PTEC; however there is substantial
data that show a profound proinﬂammatory and cytotoxic
potential of monoclonal FLC. There is a diﬀerential capacity
of any given clone of FLC to activate PTEC to produce
proinﬂammatory cytokines through activation of NFκB; this
may contribute to the inﬂammatory cell inﬁltration and
accelerated ﬁbrosis that is seen in cast nephropathy [14].
The production of these cytokines also involves mitogen-
activated protein kinases (MAPKs) ERK 1/2, JNK 1/2, and
p38 [11].
A central componentof the pathogenicity ofmonoclonal
FLC towards PTEC is mediated through the formation of
hydrogen peroxide (H2O2,); in vitro this is generated after
FLC endocytosis and indicates a high level of oxidative
stress [15]. It has subsequently been established that H2O2
production by monoclonal FLC mediates the oxidation and
activation of c-Src (a redox sensitive, nonreceptor tyrosine
kinase), an obligate step in this setting for the production
of MCP-1/CCL2 [16]. These and other studies show that
monoclonal FLCs have a greater inﬂammatory eﬀect on
PTECs than other freely ﬁltered proteins [14, 17].
T h ed y n a m i c so fs e r u mF L C( s F L C )l e v e l sa n dr e n a l
clearance is important for the interrelationship between
FLC processing by PTEC and the development of cast
nephropathy. As MM evolves, the amount of clonal FLC that
is present in glomerular ultraﬁltrate progressively increases,
ultimately to levels that overwhelm the reabsorptive capacity
of PTEC. Therefore increasing amounts of FLC are present
in ﬁltrate in the loop of Henle and the distal tubule. There
is then a diﬀerential capacity of any given clone of FLC to
aggregate with uromodulin (Tam-Horsfall protein) to form
casts [18]. One of the key determinants of cast formation is
the isoelectric point (pI) of the protein.
When the ambient pH of tubular ﬁltrate is close to the
FLC pI, the protein carries no net charge and will tend
to precipitate out of solution; proteins with a pI of 5.6–
7.3 tend to precipitate in the ascending limb of the loop
of Henle or early distal tubule while those with a pI < 5.1Bone Marrow Research 3
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Figure 2: Renal handling of LCs.
precipitate more distally (the pI of FLC has been shown to
range from 3.5 to 9.9) [18, 19]. This reﬂects the progressive
acidiﬁcation of tubular ﬂuid as it ﬂows through the distal
nephron; this consequently facilitates the precipitation of
proteins with progressively lower pIs. This may have direct
clinical relevance in the management of the acid-base
status of the individual patient which is supported by
disease model studies, where the alkalinisation of the urine
ameliorated the eﬀects of FLC on inulin clearance in rats
[20].
After precipitation of FLC, cast formation occurs when
uromodulin traps the FLC and a gel-like cast is formed.
Uromodulin is secreted at the thick ascending limb of the
loop of Henle; it is the main urinary protein in healthy
individuals and has the ability to self-aggregate into a gel
like substance and bind with many low molecular weight
proteins [21, 22]. Uromodulin has been shown to have a
speciﬁc binding site for FLC; this has been shown in animal
models to be a peptide sequence [23]. When a monoclonal
antibody against this peptide sequence was utilised there was
a reduction in FLC binding to uromodulin, and there is
great interest therefore in the potential for small molecule
blockers to reduce cast formation [23, 24]. Uromodulin
may also have an immunomodulatory role via the induction
of inﬂammatory cytokines such as TNF-α and IL-6 from
monocyte/macrophages and neutrophils [25, 26].
In conclusion, current concepts around the pathogenesis
of AKI in MM can be summarised as follows: (i) cast
nephropathy may be precipitated by dehydration, hyper-
calaemia, or nephrotoxic drugs; (ii) the precipitating factors
for cast nephropathy may themselves cause AKI in the
absence of cast formation; (iii) the direct pathogenicity of
monoclonal FLC on PTEC may also precipitate AKI; this
may occur in combination with cast nephropathy or (less
commonly) through causing acute tubular necrosis (ATN)
in the absence of cast formation. Renal impairment is more
likely to be reversible with supportive measures alone when
it is not related to cast formation [3].4 Bone Marrow Research
Our understanding of the biology of clonal FLC in
producing AKI in MM indicates that aggressive early
reduction of FLC levels may be an important factor in
promoting the recovery of kidney function. This concept is
now being supported by clinical studies that clearly show a
relationship between an early fall in sFLC levels and renal
recovery [27,28].Itis nowclearthatnovelchemotherapeutic
agents that are having a substantial impact on improving
overall outcomes for patients with MM may be particularly
important in the setting of MM and AKI, in part through
early disease response.
4.Novel Agentsand Outcomesof Patientswith
Renal Impairment
There are two crucial considerations in the assessment
of the utility of novel chemotherapeutic agents in MM
and AKI: ﬁrstly, the eﬃcacy and safety of these agents in
this setting and, secondly, the potential for these agents
to reverse renal impairment. Whilst it is self-evident that
an agent that rapidly reduces tumour burden should also
result in an improvement in renal outcome, little work
has been done to speciﬁcally address this question. This
section will focus on the clinical utility in this setting of
three novel agents used in both denovo and relapsed MM:
Thalidomide, Bortezomib and Lenalidomide. If used in the
settingofMMandAKI,theseagentsshouldprobablybeused
in regimens that incorporated dexamethasone at cytotoxic
doses; this is because they act synergistically and early work
comparing vincristine and doxorubicin alone or with high-
dose dexamethasone suggested that most of the plasma cell
reduction was due to the high-dose dexamethasone [29, 30].
Table 1 shows thosechemotherapy studiesthat havereported
both the renal characteristics of the participants and their
renal outcomes [31, 32].
4.1. Thalidomide. Thalidomide was ﬁrst developed in the
1950s and was then used widely for numerous indications;
however it was subsequently found to have devastating ter-
atogenic eﬀects and clinical use ceased. It was subsequently
postulated that the teratogenic limb defects caused by the
drug were caused by inhibition of angiogenesis, and this
prompted investigations into its potential as an antitumour
agent [41]. In 1965 the use of Thalidomide was ﬁrst reported
in a patient with MM, with a subsequent delay in disease
progression. However, it was not until 1997 that patients
were ﬁrst recruited into a clinical trial examining the eﬀect
of Thalidomide in MM [42, 43]. Since then there have
been numerous studies using the drug that have established
its eﬃcacy in MM, and it is now recommended for use
in patients with MM in a range of clinical settings [44].
Thalidomide is safe in renal impairment; it is not renally
excreted (the primary route of clearance appears to be
hepatic), and there is no dose adjustment needed for renal
impairment or in patients undergoing dialysis [45, 46].
Tosi et al. considered the use of Thalidomide-containing
regimens on the renal outcomes of patients. They enrolled
20 patients (two who were dialysis dependent) with a serum
creatinine of ≥130μmol/l and deﬁned renal recovery as
achievingaserumcreatinineof<130μmol/l[38].Allpatients
received Thalidomide at the same dose, in combination with
a range of other agents. They reported a 67% renal recovery
rate, although neither of the dialysis patients recovered
independentrenal function [38]. More recently Thalidomide
usehasbeenreported inlargernumbersofpatientswho have
beendialysisdependentatpresentation;inastudyofhighcut
oﬀ haemodialysis 14/19 patients received Thalidomide and
recovered renal function [27].
4.2. Lenalidomide. Lenalidomide is a derivative of Thalido-
mide but has a diﬀerent side eﬀect proﬁle, it was introduced
in 2004, and there has been subsequent interest in its
r o l ei nt h et r e a t m e n to fM M .T h e r eh a v eb e e ns e v e r a l
large studies of Lenalidomide in relapsed or refractory MM
that show excellent clinical outcomes with response rates
(deﬁned variously as complete, near complete, partial, or
very good partial responses) in the region of 50–60% [47–
50]. However there has been little work examining the
role of Lenalidomide in patients with renal impairment, as
traditionally trials excluded patients with renal impairment
(to varying degrees), largely because early pharmacokinetic
studies demonstrated that over 60% of the drug is excreted
in the urine as a result of glomerular ﬁltration and tubular
secretion [51]. Subsequently, Chen et al. carried out a
multicentre, open label study to investigate the eﬀect of
renal impairment and dialysis on the pharmacokinetics
of Lenalidomide. They enrolled 30 patients, whom they
stratiﬁed on the basis of renal function [52]. They conﬁrmed
that Lenalidomide is predominantly excreted by the kidneys
(80% of total drug clearance) and that a creatinine clearance
of <50mls/min is the threshold at which dose modiﬁcation
is needed in respect of renal function [50]. For patients
on dialysis there was a substantial decrease in trough
concentrations postdialysis, indicating that an extradose is
needed following dialysis treatment [50].
Dimopoulos et al. reported a subgroup analysis of
the MM-009 and MM-010 trials; this analysis focused on
the impact of renal impairment on safety and eﬃcacy of
Lenalidomide and also on the renal outcomes of the cohort
[40]. The degree of renal impairment was quantiﬁed by
the calculation of creatinine clearance by the Cockcroft-
Gault formula, and patients were divided into subgroups
depending upon their renal function at baseline; these were
mild or no renal impairment (CrCl >60mls/min), moderate
renal impairment (CrCl 30–60mls/min), or severe renal
impairment (CrCl <30mls/min); however all patients had
to have a baseline serum creatinine of <2.5mg/dL [39].
Renalrecoverywasdeﬁnedasimprovementin renalfunction
as deﬁned by transition to a subgroup with better renal
f u n c t i o n .T h e r ew a sn od i ﬀerence in disease response rates
between subgroups, and response was not inﬂuenced by the
degree of renal impairment. In moderate or severe renal
impairment, 72% of the patients had an improvement in
their renal function [40]. While individuals with very severe
renal failure were excluded and deﬁnitions for renal recovery
are not precise, this work suggests that Lenalidomide is safe
and eﬀective with a creatinine of up to 2.5mg/dL and in this
setting may improve renal function.Bone Marrow Research 5
Table 1: Renal characteristics of chemotherapy trials where both baseline renal characteristics and outcomes are reported.
Study Agents Renal Inclusion
criteria
Baseline renal
characteristics Renal outcomes
San Miguel et al.
(VISTA) [31] VMP versus MP No renal exclusions
CrCl < 30 = 6% (B),
5% (control)
CrCl 30–60 = 28% (B),
50% (control)
CrCl >60 = 46 (B),
46% (control)
Reversal = GFR >60 at end from
<50 at start
VMP group = 44% reversal
MP group = 34%
Chanan-Khan et al. [33] B+v a r i e t yo f
other agents
Dialysis dependence
mandatory
All but 1 dialysis dependent,
Median sCr = 6.8mg/dL
(3.1–12.8)? before starting
dialysis
No renal Bx
No clear defnof renal reversal
4 had “improved” renal function (1pt
never started dialysis, 2 came oﬀ dialysis
after a CR and 1 oﬀ dialysis after a MR)
Kastritis et al. [34]
VAD (or
similar),M +
hdD or D alone
Group B: hdD +
T+ / B
sCr >2mg/dL
mandatory at
enrolment
sCr >4mg/dL= 44%
sCr 2–4mg/dL = 56%
24% dialysis dependent
No renal Bx
sCr <2g/dL deﬁned as renal reversal, 83%
met this defn median TTR = 1.9mo
80% of those previously dialysed came oﬀ
dialysis
Morabito et al. [35] V+Do rV+
D+o t h e ra g e n t s No renal exclusions
CrCl 51–80 = 10.3%
CrCl 30–50 = 19.7%
CrCl <30 = 70%
12% dialysis dependent
Reversal = normalisationof CrCl, occurred
in 41% with no diﬀerences across
treatment subgroups
22% of those previously dialysed came oﬀ
dialysis
Ludwig et al. [36] V, V + D or V,
D+A
GFR <20mls/min
mandatory at
enrolment
Mean sCr 9.05mg/ml
(5.2–12)
63% dialysis dependent
No renal Bx
Median sCr fell from 9.05 to 2.1mg/dL
(0.8–2.4)
Ludwig et al. [37]V A D
GFR <50mls/min
mandatory at
enrolment
Median GFR 20.5mls/min
(3.7–49.9mls/min)
6 renal Bx (2 showed
amyloid so patients
excluded)
No deﬁned criteria for renal recovery,
median GFR increased to 48.4ml/min
(6.7–135.5mls/min),improvement in GFR
correlated with tumour response
Tosi et al. [38]T + o t h e r
sCr >130μmol/l
mandatory at
enrolment
Initial sCr for all listed,
Median = 155μmol/l
Range 131–998μmol/l
Yes, Improvement deﬁned as sCr
<130μmol/l, 12/15 responding pts had
renal recovery
Dimopoulos et al. [39]R + D N o r e n a l e x c l u s i o n s
24 had baseline CrCl, 50
(13–49), 2% dialysis
dependent at baseline
Recovery deﬁned as either CrCl, 50 to >60
or movement from one subgroup to
another, 42% of those with renal
impairment had some improvement
Dimopoulos et al. [40]R + D v e r s u s Ds C r <2.5mg/dL
CrCl >60 = 71%
CrCl 30–60 = 24%
CrCl <30 = 5%
Improvement deﬁned as movement from
one subgroup to a better one, 72% of those
who received R+D had some
improvement, data for D alone not quoted
Dimopoulos et al. [40]R + D N o r e n a l e x c l u s i o n s
CrCl >80 = 56%
CrCl 50–80 = 23.9%
CrCl 30–50 = 12.6%
CrCl <30 = 7.2%
3% dialysis dependent
26.6% had some change from one renal
subgroup to another, 12.5% had
deterioration of renal function
V: bortezomib, D: dexamethasone, M: Melphalan, P: prednisolone, A: doxorubicin, hD: high dose, T: Thalidomide, BMT: bone marrow transplant, R:
Lenalidomide,CrCl: creatinine clearance(mls/min),Bx: biopsy,sCr: serum creatinine, CR: completeresponse, MR: minimalresponse, TTR: timeto response,
GFR: glomerular ﬁltration rate.
Klein et al. reported a retrospective analysis of patients
with relapsed/refractory MM and renal impairment; the
cohort included patients who were dialysis dependent [32].
After treatment with Lenalidomide and dexamethasone
they report an improvement in renal function in 26%;
patients whose renal function stabilised or improved had
a higher frequency of PR than those whose renal function
deteriorated [41].6 Bone Marrow Research
4.3.Bortezomib. Bortezomibisaproteasomeinhibitorthatis
the ﬁrst in class, and it was synthesised in 1995 and was ﬁrst
used in humans until 1999. On the basis of a large phase II
clinical trial it was recommended by the FDA for use in
relapsed/refractory MM [52]. It undergoes hepatic clearance
with no renal clearance, and therefore no dose adjustments
are recommended for patients with impaired renal function
[53]. There have now been many large studies investigating
the use of Bortezomib, initially in relapsed/refractory MM
and more recently in de novo MM. A number of these
have analysed the drug in impaired renal function, but few
consider the renal outcomes of treated patients.
Thelargeststudyofrenaloutcomesisasubgroupanalysis
of the VISTA study; this was a randomised phase III study
comparing melphalan and prednisolone (MP) to melpha-
lan, prednisolone, and Bortezomib (VMP). However the
study excluded patients with a serum creatinine >2mg/dL
(176μmol/l) so was not applicable to patients with severe
AKI [31]. Despite this there was some indication of a beneﬁt
in the Bortezomib group with better renal outcomes in
the patients treated with the drug (44% renal recovery in
treatment arm; 34% in the control arm; P = .001 the time
to renal recovery was also faster in the VMP arm [31].
Ludwig et al. also considered the renal outcomes of
patients treated with Bortezomib; in their study it was used
as part of a BDD (Bortezomib, doxorubicin,and dexametha-
sone) regimen; they enrolled 68 patients with light-chain-
induced renal failure (deﬁning acute renal failure as a recent
decline in glomerular ﬁltration rate (GFR) <50mLs/min
where other causes of renal failure had been clinically
excluded) [37]. All patients received the same treatment
regimen, though only 58 patients were available for analysis
(seven died before the 2nd cycle, one discontinued after the
2nd cycle because of toxicity, one had progressive disease,
and one had incomplete data) [36]. They reported complete
response rates of 31% and an overall response rate of
62%, the renal outcomes of the cohort were also reported,
and the median GFR increased from 20.5mls/min (3.7–
49.9mls/min) to 48.4mls/min (6.7–135.5mls/min) [37]. It
is important to note that the number of patients with
histological evidence of cast nephropathy was small; only
six patients had had a renal biopsy (of whom two were not
enrolledbecauseofadiagnosisofamyloid), andthenumbers
requiring dialysis at the outset and the end were also not
reported.
Chanan-Khan et al. considered the use of Bortezomib
indialysis-dependentrenalimpairment.Theyretrospectively
examined the records of 24 patients who were treated for
MMandr equir eddialysisatthattime[33].Ofthe24patients
initially considered there was insuﬃcient data available in
six, so results on 18 patients were available for analysis [33].
Of the remaining patients, 23% were independent of dialysis
at analysis (one never actually needed dialysis, two became
dialysis independent after a complete response (CR) and one
after a minimal response (MR)) [33]. There was no increase
in adverse events reported compared to patients without
renal impairment [33]. As a result the authors concluded
that Bortezomib was safe and eﬀective in patients requiring
dialysis.
Encouraging evidence with Bortezomib and dexametha-
sone in patients with renal impairment has led toan Interna-
tional Myeloma Working Group recommendation that high-
dose dexamethasone and Bortezomib are the recommended
treatment for MM in patients with any degree of renal
impairment [30]. Given the previously poor prognosis for
patients with renal impairment and MM it is logical to
focus on treatment with chemotherapy regimens that have
a high response rate and where that response is associated
with a rapid early decline in tumour (and therefore clonal
FLC) load. Where Bortezomib is not available, usually as a
consequenceofcost,thenThalidomideshouldbeused,again
in combination with dexamethasone.
In addition to an evolutionin the chemotherapy options
for patients with AKI and MM, there has been a recent
reevaluation of the role of extracorporeal removal of sFLC.
Whilst this may seem an attractive addition to therapies that
are available, it is critical to understand that this adjunctive
therapy will only add beneﬁt in the setting of eﬀective
chemotherapy. Furthermore, any proposed use must be
validated by properly designed prospective randomised
controlled trials.
5.ExtracorporealLCRemovalStrategies
Plasma exchange has been variably used in clinical practice
f o rt h er e m o v a lo fF L C ;h o w e v e r ,t h e r ei sn oc o n v i n c i n g
evidence of beneﬁt compared to treatment regimens that do
not include plasma exchange. More recently, novel protein
permeable dialysis membranes have been developed, and
their utility in FLC removal has attracted considerable
interest.
5.1. Plasma Exchange. Plasma exchange (PE) involves ex-
tracorporeal processing of a patient’s blood to remove
pathogenic substances from the plasma; dependent on the
clinical indication these can include autoantibodies, cryo-
globulins, or other abnormal plasma proteins or immune
complexes [54] .As i n g l ep l a s m ae x c h a n g er e m o v e sa p p r o x -
imately 75% of the patient’s own plasma and the abnormal
constituent in the plasma [54]. Therefore PE was considered
a sf o rt h er e m o v a lo fr e m o v eF L C si nM Ma n dw a s
investigated in a series of studies. The largest and most
robust study to date, reported by Clark et al., examined the
outcomes of 104 patients (of whom 97 completed 6-month
followup) with acute renal failure at the time of presentation
of MM [55]. There were several design shortfalls in the
study; these included the absence of histological diagnosis
of cast nephropathy and the presence of dialysis dependency
at randomisation in only 28% of those recruited [55]. The
patients were randomised to receive either conventional
therapy with the addition of between ﬁve and seven plasma
exchanges orconventionaltherapy alone. The results showed
that there was no beneﬁt derived from plasma exchange by a
composite end point of death, dialysis dependence, or renal
function at six months [55].
Other studies of PE have shown conﬂicting results,
but these are all limited by small sample sizes and other
methodological ﬂaws [56, 57]. Collectively, these studiesBone Marrow Research 7
raised questions about why PE is ineﬀective. The most
important reason probably relates to the short duration
of the treatment, which results in removal of FLC from
the intravascular space only. As 85% of the total FLC load
is in the extravascular compartment, this leads to rapid
redistribution following PE of FLC into the intravascular
compartment [58]. As a consequence, PE has a limited
impact on the overall exposure of the kidneys to FLC. One
obvious way to address is to utilise an extended treatment
that removes FLC over a prolonged period of time and
therefore removes FLCs that are undergoing redistribution
from the extravascular to the intravascular compartment;
the recent introduction of protein permeable dialysers into
clinical practice has led to the practical assessment of the
utilityofextendedextracorporealremovalofFLCinMMand
AKI.
6.HighCut-Off(HCO)Haemodialysis
Recently, clinical researchers have utilised a newer type of
larger pore dialysis membrane (the Gambro HCO 1100, ini-
tially developed for cytokine removal in critically ill patients
on intensive care units by continuous dialysis modalities)
and showed high clearances of both isotypes of FLC both in
vitro and in vivo [59]. This ﬁnding was consistent with the
physical characteristics of the dialyser, which has an eﬀective
cut-oﬀ for the removal of molecules of a molecular weight
of <50Kd. In the initial report, the eﬃcacy of the dialyser
was reinforced by signiﬁcant reductions in serum FLC levels
in patients with MM and renal failure on extended dialysis
sessions [59].
This work was followed by a pilot study of HCO
dialysis in MM. Nineteen patients with biopsy proven cast
nephropathyand severeAKIrequiring dialysiswere enrolled,
treated with chemotherapy regimens that included novel
agents, and prescribed extended HCO dialysis sessions of
up to 8 hours a day [27]. The treatment was well tolerated,
and recovery of renal function to independence of dialysis
was seen in 14 patients (74% renal recovery). Of particular
interest in this study was the observation that there was an
early and sustained reduction of sFLC levelsin those patients
who recovered kidney function; those patientswho had early
interruptions in chemotherapy did not have early reductions
inFLClevelsand usuallydid notrecoverindependentkidney
function [27].
These initial results have led to the development of
EuLITE,arandomisedcontrolledtrialofHCOdialysisversus
conventional dialysis in patients with de novo MM, biopsy
proven cast nephropathy, and dialysis-dependent acute kid-
ney injury at presentation. All patients receive chemotherapy
with Bortezomib, doxorubicin, and dexamethasone. The
study is ongoing and has a primary outcome measure of
dialysis independence at 3 months [60].
7.Conclusions
Multiple myeloma remains an incurable disease although
long-term outcomes are improving. However patients with
AKI,particularlythoserequiringdialysistreatment,continue
to have poor outcomes. A greater understanding of the
pathogenesis of cast nephropathy may lead to successful
prevention strategies and improvements in chemotherapy
and the emergence of an eﬀective method of LC removal
contribute to future improvements in clinical outcomes for
those aﬀect.
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